amikacin vs oritavancin
Side-by-side comparison of amikacin and oritavancin Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Amikin
Orbactiv
Amikacin is an antibiotic medicine. It fights serious infections caused by certain types of bacteria.
KIMYRSA is an antibiotic medicine. It is used to treat serious skin infections caused by certain bacteria.
Amikacin treats serious infections caused by bacteria. This includes infections in the blood, lungs, bones, joints, brain, skin, and abdomen. It can also treat burns, post-surgery infections, and complicated urinary tract infections.
KIMYRSA treats acute bacterial skin and skin structure infections (ABSSSI) in adults. These infections are caused by specific Gram-positive bacteria. KIMYRSA can fight Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis, among others. Your doctor will determine if KIMYRSA is the right medicine for your infection.
Amikacin belongs to a class of drugs called aminoglycosides. It works by stopping the growth of bacteria. This helps your body fight off the infection.
KIMYRSA is a lipoglycopeptide antibiotic. It works by stopping bacteria from building their cell walls. This kills the bacteria and helps to clear the infection.
No common side effects listed.
- • Headache
- • Nausea
- • Vomiting
- • Abscesses on limbs or under the skin
- • Diarrhea
- Off Label Use 1,908
- Drug Ineffective 1,673
- Cough 1,620
- Dyspnoea 1,556
- Hospitalisation 1,360
- Off Label Use 173
- Pruritus 162
- Urticaria 105
- Rash 84
- Chills 83
Amikacin can potentially cause hearing loss and kidney damage. Tell your doctor if you have kidney problems or are taking other medicines that can affect your hearing or kidneys. Your doctor should closely monitor you for hearing and kidney problems during treatment. This drug can also cause muscle weakness or breathing problems, especially if you are also taking anesthesia or certain muscle relaxants.
You should not take KIMYRSA if you are using intravenous heparin. Do not use heparin for 5 days (120 hours) after getting KIMYRSA. Serious allergic reactions, including anaphylaxis, have been reported. Tell your doctor right away if you have signs of an allergic reaction.
Tell your doctor if you are pregnant or breastfeeding. Amikacin may harm your unborn baby. It is not known if amikacin passes into breast milk.
It is not known if KIMYRSA can harm an unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if KIMYRSA passes into breast milk. Talk to your doctor about the best way to feed your baby if you take KIMYRSA.
Also Compare — Nearby Drugs
Compare amikacin with
Compare oritavancin with
How to Read This amikacin vs oritavancin Comparison
amikacin is classified in the Aminoglycoside Antibiotic drug class, while oritavancin sits within the Lipoglycopeptide Antibiotic class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, amikacin has 8,117 submissions while oritavancin has 607. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between amikacin and oritavancin — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.